Exact Mass: 437.1937
Exact Mass Matches: 437.1937
Found 500 metabolites which its exact mass value is equals to given mass value 437.1937
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fluphenazine
Fluphenazine is only found in individuals that have used or taken this drug. It is a phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
fMLP;N-Formyl-MLF
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
Disopyramid phosphate
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Alobresib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
Lagerstroemine
Lagerstroemine is found in fruits. Lagerstroemine is an alkaloid from Plantago psyllium seeds (African plantain
Benzoylphenylalanyl-alanyl-proline
(S)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-succinic acid
N-Formyl-Met-Leu-Phe
Pazopanib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
(2S)-2-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]butanedioic acid
n-Formyl-methionyl-leucyl-phenyl-alanine
([1,2]Ra,32S)-16-hydroxy-24,5-dimethoxy-(32rH,34tH,39ac)-3-octahydro-4-oxa-1(1,3),2(1,2)-dibenzena-3(4,2)-quinolizina-cycloheptaphan-5-one|2-hydroxy-4,5-dimethoxy-13,14-dihydro-(10alpha)-lythran-12-one|Decamin|Decamine|dihydrovertine
(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-3-hydroxy-4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-phenethyl amide|sakerinol A
(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-2-[4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-phenyl]-2-hydroxyethyl amide|beta-hydroxygerambullol|??-Hydroxygerambullol
TRIPARANOL
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites
WWL70
WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.
Pazopanib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
Fluphenazine (oxide)
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
Ala Ala Asn Tyr
Ala Ala Tyr Asn
Ala Phe Asn Ser
Ala Phe Ser Asn
Ala Gly Lys Tyr
Ala Gly Gln Tyr
Ala Gly Tyr Lys
Ala Gly Tyr Gln
Ala His Asn Pro
Ala His Pro Asn
Ala Lys Gly Tyr
Ala Lys Tyr Gly
Ala Asn Ala Tyr
Ala Asn Phe Ser
Ala Asn His Pro
Ala Asn Pro His
Ala Asn Ser Phe
Ala Asn Tyr Ala
Ala Pro His Asn
Ala Pro Asn His
Ala Gln Gly Tyr
Ala Gln Tyr Gly
Ala Ser Phe Asn
Ala Ser Asn Phe
Ala Tyr Ala Asn
Ala Tyr Gly Lys
Ala Tyr Gly Gln
Ala Tyr Lys Gly
Ala Tyr Asn Ala
Ala Tyr Gln Gly
Cys Gly Lys Met
Cys Gly Met Lys
Cys Lys Gly Met
Cys Lys Met Gly
Cys Lys Ser Thr
Cys Lys Thr Ser
Cys Met Gly Lys
Cys Met Lys Gly
Cys Asn Thr Thr
Cys Gln Ser Thr
Cys Gln Thr Ser
Cys Ser Lys Thr
Cys Ser Gln Thr
Cys Ser Thr Lys
Cys Ser Thr Gln
Cys Thr Lys Ser
Cys Thr Asn Thr
Cys Thr Gln Ser
Cys Thr Ser Lys
Cys Thr Ser Gln
Cys Thr Thr Asn
Phe Ala Asn Ser
Phe Ala Ser Asn
Phe Gly Lys Ser
Phe Gly Asn Thr
Phe Gly Gln Ser
Phe Gly Ser Lys
Phe Gly Ser Gln
Phe Gly Thr Asn
Phe Lys Gly Ser
Phe Lys Ser Gly
Phe Asn Ala Ser
Phe Asn Gly Thr
Phe Asn Ser Ala
Phe Asn Thr Gly
Phe Gln Gly Ser
Phe Gln Ser Gly
Phe Ser Ala Asn
Phe Ser Gly Lys
Phe Ser Gly Gln
Phe Ser Lys Gly
Phe Ser Asn Ala
Phe Ser Gln Gly
Phe Thr Gly Asn
Phe Thr Asn Gly
Gly Ala Lys Tyr
Gly Ala Gln Tyr
Gly Ala Tyr Lys
Gly Ala Tyr Gln
Gly Cys Lys Met
Gly Cys Met Lys
Gly Phe Lys Ser
Gly Phe Asn Thr
Gly Phe Gln Ser
Gly Phe Ser Lys
Gly Phe Ser Gln
Gly Phe Thr Asn
Gly His Pro Gln
Gly His Gln Pro
Gly Lys Ala Tyr
Gly Lys Cys Met
Gly Lys Phe Ser
Gly Lys Met Cys
Gly Lys Ser Phe
Gly Lys Tyr Ala
Gly Met Cys Lys
Gly Met Lys Cys
Gly Asn Phe Thr
Gly Asn Thr Phe
Gly Pro His Gln
Gly Pro Gln His
Gly Gln Ala Tyr
Gly Gln Phe Ser
Gly Gln His Pro
Gly Gln Pro His
Gly Gln Ser Phe
Gly Gln Tyr Ala
Gly Ser Phe Lys
Gly Ser Phe Gln
Gly Ser Lys Phe
Gly Ser Gln Phe
Gly Thr Phe Asn
Gly Thr Asn Phe
Gly Tyr Ala Lys
Gly Tyr Ala Gln
Gly Tyr Lys Ala
Gly Tyr Gln Ala
His Ala Asn Pro
His Ala Pro Asn
His Gly Pro Gln
His Gly Gln Pro
His Asn Ala Pro
His Asn Pro Ala
His Pro Ala Asn
His Pro Gly Gln
His Pro Asn Ala
His Pro Gln Gly
His Gln Gly Pro
His Gln Pro Gly
Lys Ala Gly Tyr
Lys Ala Tyr Gly
Lys Cys Gly Met
Lys Cys Met Gly
Lys Cys Ser Thr
Lys Cys Thr Ser
Lys Phe Gly Ser
Lys Phe Ser Gly
Lys Gly Ala Tyr
Lys Gly Cys Met
Lys Gly Phe Ser
Lys Gly Met Cys
Lys Gly Ser Phe
Lys Gly Tyr Ala
Lys Met Cys Gly
Lys Met Gly Cys
Lys Ser Cys Thr
Lys Ser Phe Gly
Lys Ser Gly Phe
Lys Ser Thr Cys
Lys Thr Cys Ser
Lys Thr Ser Cys
Lys Tyr Ala Gly
Lys Tyr Gly Ala
Met Cys Gly Lys
Met Cys Lys Gly
Met Gly Cys Lys
Met Gly Lys Cys
Met Lys Cys Gly
Met Lys Gly Cys
Met Asn Ser Ser
Met Ser Asn Ser
Met Ser Ser Asn
Asn Ala Ala Tyr
Asn Ala Phe Ser
Asn Ala His Pro
Asn Ala Pro His
Asn Ala Ser Phe
Asn Ala Tyr Ala
Asn Cys Thr Thr
Asn Phe Ala Ser
Asn Phe Gly Thr
Asn Phe Ser Ala
Asn Phe Thr Gly
Asn Gly Phe Thr
Asn Gly Thr Phe
Asn His Ala Pro
Asn His Pro Ala
Asn Met Ser Ser
Asn Pro Ala His
Asn Pro His Ala
Asn Ser Ala Phe
Asn Ser Phe Ala
Asn Ser Met Ser
Asn Ser Ser Met
Asn Thr Cys Thr
Asn Thr Phe Gly
Asn Thr Gly Phe
Asn Thr Thr Cys
Asn Tyr Ala Ala
Pro Ala His Asn
Pro Ala Asn His
Pro Gly His Gln
Pro Gly Gln His
Pro His Ala Asn
Pro His Gly Gln
Pro His Asn Ala
Pro His Gln Gly
Pro Asn Ala His
Pro Asn His Ala
Pro Pro Pro Gln
Pro Pro Gln Pro
Pro Gln Gly His
Pro Gln His Gly
Pro Gln Pro Pro
Gln Ala Gly Tyr
Gln Ala Tyr Gly
Gln Cys Ser Thr
Gln Cys Thr Ser
Gln Phe Gly Ser
Gln Phe Ser Gly
Gln Gly Ala Tyr
Gln Gly Phe Ser
Gln Gly His Pro
Gln Gly Pro His
Gln Gly Ser Phe
Gln Gly Tyr Ala
Gln His Gly Pro
Gln His Pro Gly
Gln Pro Gly His
Gln Pro His Gly
Gln Pro Pro Pro
Gln Ser Cys Thr
Gln Ser Phe Gly
Gln Ser Gly Phe
Gln Ser Thr Cys
Gln Thr Cys Ser
Gln Thr Ser Cys
Gln Tyr Ala Gly
Gln Tyr Gly Ala
Ser Ala Phe Asn
Ser Ala Asn Phe
Ser Cys Lys Thr
Ser Cys Gln Thr
Ser Cys Thr Lys
Ser Cys Thr Gln
Ser Phe Ala Asn
Ser Phe Gly Lys
Ser Phe Gly Gln
Ser Phe Lys Gly
Ser Phe Asn Ala
Ser Phe Gln Gly
Ser Gly Phe Lys
Ser Gly Phe Gln
Ser Gly Lys Phe
Ser Gly Gln Phe
Ser Lys Cys Thr
Ser Lys Phe Gly
Ser Lys Gly Phe
Ser Lys Thr Cys
Ser Met Asn Ser
Ser Met Ser Asn
Ser Asn Ala Phe
Ser Asn Phe Ala
Ser Asn Met Ser
Ser Gln Phe Gly
Ser Gln Gly Phe
Ser Thr Cys Lys
Ser Thr Lys Cys
Thr Cys Lys Ser
Thr Cys Ser Lys
Thr Phe Gly Asn
Thr Phe Asn Gly
Thr Gly Phe Asn
Thr Gly Asn Phe
Thr Lys Cys Ser
Thr Lys Ser Cys
Thr Asn Phe Gly
Thr Asn Gly Phe
Thr Ser Cys Lys
Thr Ser Lys Cys
6-Hydroxy Doxazosin
Tyr Ala Ala Asn
Tyr Ala Gly Lys
Tyr Ala Gly Gln
Tyr Ala Lys Gly
Tyr Ala Asn Ala
Tyr Ala Gln Gly
Tyr Gly Ala Lys
Tyr Gly Ala Gln
Tyr Gly Lys Ala
Tyr Gly Gln Ala
Tyr Lys Ala Gly
Tyr Lys Gly Ala
Tyr Asn Ala Ala
Tyr Gln Ala Gly
Tyr Gln Gly Ala
D-Cloprostenol methyl amide
Lagerstremine
9,9-Dimethyl-N-[1,1:4,1-terphenyl]-4-yl-9H-fluoren-2-amine
benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside
2-(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-3-NAPHTHALEN-2-YL-PROPIONIC ACID
Oxolamine citrate
D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents
N-([1,1:3,1-terphenyl]-5-yl)-9,9-dimethyl-9H-fluoren-2-amine
2-PHENYLCARBAMOYL-1,4-NAPHTHOQUINONE-4-(4-DIETHYLAMINO-2-METHYLPHENYL)IMINE
(6-Chloro-1-(2-(dimethylamino)ethyl)indol-3-yl)-spiro(1H-isobenzofuran-3,4-piperidine)-1-yl-methanone
N-{(1s,2r)-2-Hydroxy-1-[(Hydroxyamino)carbonyl]propyl}-4-{[4-(Morpholin-4-Ylmethyl)phenyl]ethynyl}benzamide
Amperozide hydrochloride
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist
Cyclazosin
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
N-[1,4-dioxo-3-(4-phenyl-1-piperazinyl)-2-naphthalenyl]benzamide
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c:1,2-f]pyrimidinecarboxamide
1,3-Dimethyl-8-[methyl-(phenylmethyl)amino]-7-[2-(2-pyrimidinylthio)ethyl]purine-2,6-dione
1-(3-(2,4-Dimethylthiazol-5-YL)-4-oxo-2,4-dihydroindeno[1,2-C]pyrazol-5-YL)-3-(4-methylpiperazin-1-YL)urea
Meropenem Hydrate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
For-Met-Leu-Phe-OH
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
Benzoylphenylalanyl-alanyl-proline
(S)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-succinic acid
(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-3-[[(2S)-2-azaniumyl-5-[diaminomethylidene(methyl)azaniumyl]-3-methylpentanoyl]amino]-3,6-dihydro-2H-pyran-2-carboxylate
2-alpha,omega-Hexadecanedioyl-lysophosphatidic acid
1-alpha,omega-Hexadecanedioyl-glycerol-3-phosphate
[(4S)-4-amino-5-[[(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-2-carboxy-3,6-dihydro-2H-pyran-3-yl]amino]-3-methyl-5-oxopentyl]-(diaminomethylidene)-methylazanium
2-(N-[2-[(2-formamido-4-methylsulfanylbutanoyl)amino]-4-methylpentanoyl]anilino)propanoic acid
(2S)-2-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]butanedioic acid
4-[[[2-(4-methoxyphenyl)-3-oxo-1H-isoindol-4-yl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester
[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(2-furanyl)methanone
(3R,3As,7R,7aS)-2-benzyl-3-[4-fluoro-3-[(E)-2-phenylethenyl]phenyl]-7-methyl-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
(4-Tert-butylphenyl)-[2-(4-fluorophenyl)-8-methyl-3-sulfanylidene-1,4,8-triazaspiro[4.5]dec-1-en-4-yl]methanone
1-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-3-(4-methoxyphenyl)-1-(2-oxolanylmethyl)urea
3-(2,3-dimethoxyphenyl)-1-(9-methyl-2-phenyl-9H-imidazo[1,2-a]benzimidazol-3-yl)prop-2-en-1-one
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[(2R,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2R,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2S,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(1S,3S,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3R,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
(6S,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
N-[(2S,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2S,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2S,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2R,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(2R,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]cyclohexanecarboxamide
N-[(1R,3S,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-N-[(4-fluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-N-[(4-fluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-2-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(3-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(6R,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-methylsulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-methylsulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(4-fluorophenyl)-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(4-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-methylsulfonyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-methylsulfonyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(2R,4S)-2-[(1R)-1-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-2-(butylamino)-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylate
(2S)-2-(2-ethoxyanilino)-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]propanamide
methyl (2S)-2-[6-(2-ethylphenyl)-4,7-dimethyl-1,3-dioxopurino[7,8-a]imidazol-2-yl]-3-methylbutanoate
PE(14:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
CTX-0294885
CTX-0294885 is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer[1].
n-(2-hydroxy-2-{4-[(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid
(1s)-1-(8-hydroxy-3-{[(1z)-3-methoxy-3-oxoprop-1-en-1-yl]carbamoyl}-9h-pyrido[3,4-b]indol-1-yl)ethyl (2z)-2-methylbut-2-enoate
β-hydroxygerambullol
{"Ingredient_id": "HBIN018158","Ingredient_name": "\u03b2-hydroxygerambullol","Alias": "NA","Ingredient_formula": "C22H31NO6S","Ingredient_Smile": "CC(=CCOC1=CC=C(C=C1)C(CNC(=O)C=CS(=O)(=O)C)O)CCC=C(C)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10139","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}